| Literature DB >> 23535595 |
G M Tannahill1, A M Curtis, J Adamik, E M Palsson-McDermott, A F McGettrick, G Goel, C Frezza, N J Bernard, B Kelly, N H Foley, L Zheng, A Gardet, Z Tong, S S Jany, S C Corr, M Haneklaus, B E Caffrey, K Pierce, S Walmsley, F C Beasley, E Cummins, V Nizet, M Whyte, C T Taylor, H Lin, S L Masters, E Gottlieb, V P Kelly, C Clish, P E Auron, R J Xavier, L A J O'Neill.
Abstract
Macrophages activated by the Gram-negative bacterial product lipopolysaccharide switch their core metabolism from oxidative phosphorylation to glycolysis. Here we show that inhibition of glycolysis with 2-deoxyglucose suppresses lipopolysaccharide-induced interleukin-1β but not tumour-necrosis factor-α in mouse macrophages. A comprehensive metabolic map of lipopolysaccharide-activated macrophages shows upregulation of glycolytic and downregulation of mitochondrial genes, which correlates directly with the expression profiles of altered metabolites. Lipopolysaccharide strongly increases the levels of the tricarboxylic-acid cycle intermediate succinate. Glutamine-dependent anerplerosis is the principal source of succinate, although the 'GABA (γ-aminobutyric acid) shunt' pathway also has a role. Lipopolysaccharide-induced succinate stabilizes hypoxia-inducible factor-1α, an effect that is inhibited by 2-deoxyglucose, with interleukin-1β as an important target. Lipopolysaccharide also increases succinylation of several proteins. We therefore identify succinate as a metabolite in innate immune signalling, which enhances interleukin-1β production during inflammation.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23535595 PMCID: PMC4031686 DOI: 10.1038/nature11986
Source DB: PubMed Journal: Nature ISSN: 0028-0836 Impact factor: 49.962